Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.

Abstract

These data provide new insights into how DBM regulates AR function and cell growth, as well as providing promising evidence to support DBM as a chemotherapeutic agent for prostate cancer through suppression of the function of the androgen receptor.